Drug Use Disorders Identification Test – DUDIT

1. Abstract

The Drug Use Disorders Identification Test (DUDIT) is an 11-item self-administered screening instrument engineered to identify individuals with drug-related problems, ranging from hazardous and harmful drug consumption to severe substance dependence. Developed under the auspices of Anne H. Berman and colleagues at the Karolinska Institutet in Stockholm, Sweden, the DUDIT was purposely designed as a parallel companion to the Alcohol Use Disorders Identification Test (AUDIT) developed by the World Health Organization. While the AUDIT focuses strictly on alcohol-related patterns, the DUDIT encompasses all non-alcohol psychoactive substances, including illicit drugs and non-prescribed or improperly consumed prescription pharmaceuticals. The instrument captures three primary behavioral and clinical domains: drug consumption patterns (Items 1–4), signs of dependence or neurobiological craving (Items 5–8), and negative social, psychological, or physical consequences resulting from drug use (Items 9–11).

Items 1 through 9 are scored on a 5-point Likert scale ranging from 0 to 4, whereas Items 10 and 11 utilize a 3-point rating scale scored as 0, 2, or 4 points, producing a maximum total score of 44. Psychometric investigations across clinical detoxification units, prison and probation populations, psychiatric facilities, and community cohorts have repeatedly demonstrated high internal consistency, with Cronbach’s alpha typically ranging between .80 and .94. Exploratory and confirmatory factor analyses generally corroborate an overarching unidimensional general substance severity construct alongside a robust two-factor conceptualization distinguishing drug consumption from drug-related problems and dependence symptoms. DUDIT provides critical diagnostic utility across medical, correctional, and epidemiological settings, demonstrating superior sensitivity and specificity in identifying DSM-IV, DSM-5, and ICD-10 substance use disorders.

2. Keywords

Drug Use Disorders Identification Test, DUDIT, substance use disorder, psychometrics, screening instrument, addiction assessment, drug dependence, harmful drug use, clinical assessment, substance abuse

3. Authors

The Drug Use Disorders Identification Test was constructed and validated by a multidisciplinary research team led by Anne H. Berman, Ph.D., licensed clinical psychologist and Professor of Clinical Psychology at the Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden, and Uppsala University. The foundational design of the questionnaire dates back to clinical initiatives in the late 1990s and early 2000s, culminated in the seminal psychometric validation published in 2005.

Key co-investigators and academic contributors include:

• Hans Bergman, Ph.D. – Department of Clinical Neuroscience, Karolinska Institutet, and Department of Psychology, Stockholm University, Stockholm, Sweden.
• Torkel Palmstierna, M.D., Ph.D. – Centre for Psychiatry Research, Karolinska Institutet, Stockholm, Sweden, and Department of Mental Health, Norwegian University of Science and Technology (NTNU), Trondheim, Norway.
• Frida Schlyter, M.Sc. – National Prison and Probation Administration (Kriminalvården), Research and Development Unit, Norrköping, Sweden.

Correspondence regarding the original Swedish and English validation studies can be directed to the Centre for Psychiatry Research, Department of Clinical Neuroscience, Karolinska Institutet, Solna, SE-171 77 Stockholm, Sweden.

4. Purpose

The primary purpose of the Drug Use Disorders Identification Test (DUDIT) is to offer clinicians, researchers, and public health practitioners a brief, reliable, and standardized screening mechanism to identify illicit substance use, non-medical pharmaceutical use, and substance use pathology. Prior to the development of the DUDIT, clinical medicine lacked an internationally calibrated instrument that mirrored the conceptual architecture of the AUDIT for psychoactive agents other than alcohol. Clinicians frequently relied on extended semi-structured clinical interviews, such as the Addiction Severity Index (ASI) or the Structured Clinical Interview for DSM Disorders (SCID), which are time-intensive, require extensive specialized training, and cannot be readily embedded into busy triage routines, primary care visits, emergency rooms, or correctional intakes.

The DUDIT addresses this critical operational gap by fulfilling multiple overlapping clinical and investigative objectives:

• Early Detection in General Settings: The scale functions as an early triage tool in primary health clinics, general outpatient medicine, psychiatric triage stations, and university student health services to uncover harmful or hazardous drug-taking practices before acute medical decompensation or chronic legal entanglements occur.
• Secondary Prevention and Brief Intervention: Mirroring the public health framework of Screening, Brief Intervention, and Referral to Treatment (SBIRT), DUDIT scores provide an objective baseline that clinicians can utilize to provide non-judgmental motivational feedback, foster cognitive dissonance regarding drug consumption, and prompt structured behavioral change.
• Triage within Forensic and Correctional Services: The DUDIT has attained widespread institutional utilization within criminal justice systems, probation environments, and prison reception centers to delineate non-problematic offenders from those requiring compulsory or voluntary addiction rehabilitation programming.
• Outcome Measurement in Longitudinal Research: Because its quantitative scoring range is expansive (0 to 44), the DUDIT is routinely deployed in clinical trials and naturalistic addiction cohort studies to monitor trajectories of recovery, reduction in drug-related harm, treatment adherence, or symptom relapse over time.

The instrument was strategically engineered to complement the AUDIT, allowing clinicians to administer both screeners concurrently. This combined application provides a comprehensive, 360-degree assessment of poly-substance and alcohol interactions, yielding a holistic snapshot of an individual’s chemical dependency profile.

5. Psychological Construct

The DUDIT measures the multifaceted latent construct of drug use disorder severity across a continuum extending from benign experimentation to severe chemical dependence. In accordance with the nosological guidelines established by the World Health Organization (ICD-10/ICD-11) and the American Psychiatric Association (DSM-IV-TR and DSM-5), the instrument segments this broad construct into three operationalized dimensions:

1. Drug Consumption and Intake Patterns (Items 1–4)

This sub-domain quantifies the quantitative and behavioral parameters of drug exposure. It gauges the objective chronicity, intensity, and behavioral clustering of substance intake:

• Frequency of Non-Alcohol Drug Use (Item 1): Measures the baseline temporal regularity of non-prescribed chemical exposure over a standard multi-tier frequency gradient.
• Polydrug Use on the Same Occasion (Item 2): Evaluates the concurrent ingestion of two or more distinct pharmacologic classes (e.g., combining stimulants with sedatives or cannabis with prescription opioids), a behavioral marker directly tied to elevated overdose mortality and severe neurotoxic sequelae.
• Typical Daily Dosage and Frequency (Item 3): Gauges the volumetric velocity of consumption on an active drug day, identifying high-density bingeing behaviors.
• Heavy Intoxication / Drug Influence (Item 4): Evaluates the frequency with which the user experiences profound psychoactive impairment, reflecting loss of functional tolerance control.

2. Dependence Symptoms and Impaired Volition (Items 5–8)

This dimension operationalizes the neurocognitive and behavioral hallmarks of chemical dependency, centered on loss of agency, compulsive seeking, and somatic or psychological neuroadaptation:

• Craving and Strong Longing (Item 5): Captures cognitive salience and subjective compulsivity, mirroring the DSM-5 criterion of craving where an individual feels an irresistible urge to administer the chemical agent.
• Impaired Control over Consumption (Item 6): Assesses behavioral dysregulation, characterized by the failure to terminate consumption once self-administration has commenced.
• Role Obligation Failure (Item 7): Measures functional behavioral decrement, reflecting the degree to which intoxication or drug-seeking supplants vocational, domestic, familial, or educational responsibilities.
• Morning Substance Use / Eye-Opener (Item 8): Measures biological or psychological withdrawal relief, wherein the individual self-administers the substance upon waking to stave off autonomic rebound, tremor, depressive crash, or acute psychomotor agitation.

3. Negative Consequences and Harmful Use (Items 9–11)

This component captures the secondary downstream externalities and adverse psychosocial or somatic sequelae induced by chemical intake:

• Guilt Feelings and Moral Distress (Item 9): Evaluates the internal affective cost of substance use, capturing psychological distress, bad conscience, and post-intoxication cognitive dissonance.
• Physical or Mental Harm (Item 10): Assesses trauma, psychological crises, physiological morbidity, or physical injuries sustained either by the user or by third parties as an immediate consequence of the individual’s drug consumption.
• Social Concern and Intervention (Item 11): Gathers external collateral markers of behavioral pathology, measuring whether family members, intimate partners, employers, or healthcare providers have articulated concern or formally advised cessation.

6. Theoretical Framework

The DUDIT is grounded theoretically in the public health spectrum model of substance misuse, the biopsychosocial model of addiction, and the neuroadaptation paradigm articulated across contemporary behavioral psychiatry.

Historically, substance misuse was conceptualized through a categorical, moral, or purely binary disease model: an individual was either classified as an “addict” or deemed “normal.” The public health model pioneered by Griffith Edwards and codified by the World Health Organization dismantled this binary paradigm, introducing a dimensional continuum ranging from: (a) non-use, (b) low-risk use, (c) hazardous use (patterns carrying risk of harm without current diagnostic damage), (d) harmful use (use causing explicit physical, psychiatric, or social injury), to (e) substance dependence. The DUDIT operationalizes this dimensional spectrum, demonstrating that clinical intervention is most cost-effective and preventative when targeted at the hazardous and harmful phases before irreversible biological or structural damage occurs.

Furthermore, the DUDIT incorporates concepts from Neurobiological Incentive Sensitization Theory (Robinson & Berridge) and Allostatic Models of Addiction (Koob & Le Moal). According to incentive sensitization, chronic drug exposure rewires mesolimbic dopaminergic pathways, causing the neural substrate underlying “wanting” (craving; captured in DUDIT Item 5) to become progressively dissociated from “liking” (hedonic pleasure). As allostatic dysregulation deepens, positive reinforcement shifts to negative reinforcement, where substance intake is maintained primarily to escape dysphoria, psychomotor distress, or autonomic withdrawal symptoms (captured directly in DUDIT Item 8, morning use to alleviate post-drug physiological decrement).

At the cognitive-behavioral level, the instrument relies on Bandura’s self-efficacy frameworks and contemporary motivational psychology (Prochaska and DiClemente’s Transtheoretical Stages of Change). By systematically probing negative consequences (Items 9–11) alongside impaired control (Item 6), the DUDIT highlights the erosion of perceived behavioral control, providing an empirical mirror that clinicians can leverage in motivational interviewing dialogues to advance an individual from pre-contemplation to active contemplation of behavioral modification.

7. Validity

The psychometric validity of the DUDIT has been evaluated across diverse international settings, languages, and clinical populations, establishing robust construct, criterion, convergent, and discriminant validity.

Criterion and Predictive Validity

In the foundational psychometric study conducted by Berman et al. (2005), the DUDIT was administered to three distinct cohorts: a general Swedish population sample (n = 1,058), a correctional probation sample (n = 203), and a clinical detoxification cohort (n = 78). Using the Mini-International Neuropsychiatric Interview (M.I.N.I.) and DSM-IV criteria as gold standards, Receiver Operating Characteristic (ROC) analyses revealed outstanding diagnostic accuracy:

• Substance Abuse/Harmful Use: The area under the ROC curve (AUC) was 0.93, indicating exceptional discriminative efficiency.
• Substance Dependence: The AUC was 0.94 in clinical and correctional cohorts.
• Sensitivity and Specificity: In general population and outpatient psychiatric samples, an optimal cut-off score of ≥6 for men yielded a sensitivity of 0.90 and a specificity of 0.88 for detecting drug-related problems. For women, an optimal cut-off score of ≥2 yielded a sensitivity of 0.90 and a specificity of 0.88. The lower threshold for women reflects well-documented epidemiological differences in drug exposure rates and gendered vulnerability to neurobiological escalation.
• Dependence Cut-Off: For diagnosing severe substance dependence, a total cut-off score of ≥25 yielded optimal balance, demonstrating high specificity (>0.90) in forensic and specialized inpatient detoxification centers.

Convergent and Concurrent Validity

Convergent validity has been established by cross-correlating DUDIT total scores with established diagnostic and psychometric metrics:

• High Pearson correlations have been reported between DUDIT and the Drug Abuse Screening Test (DAST-10 and DAST-20), with correlation coefficients consistently exceeding r = .82 (Volk et al., 2016).
• Moderate to strong positive correlations (r = .55 to .74) occur with the Addiction Severity Index (ASI) drug composite score and biological urine toxicology screens.
• Concurrent administration alongside the AUDIT demonstrates discriminant validity: while clients with polydrug abuse exhibit elevations across both instruments, patients with isolated alcohol dependence display high AUDIT scores with near-zero DUDIT scores, verifying that the instrument does not cross-react with legal ethanol misuse.

8. Reliability

The DUDIT exhibits high internal consistency, inter-item correlation, and temporal stability across cultural contexts and patient cohorts.

Internal Consistency

• In the original psychometric evaluation by Berman et al. (2005), Cronbach’s alpha for the entire 11-item instrument was .94 in the clinical addiction cohort and .80 in the criminal justice sample.
• A large validation study of Swedish prison inmates conducted by Durbeej et al. (2010) reported an overall alpha coefficient of .92.
• International adaptations have replicated these metrics: the Spanish version (alpha = .91; Hildebrand et al., 2015), the German version (alpha = .89; Hillemacher et al., 2011), the French validation (alpha = .90), and the Chinese clinical adaptation (alpha = .93) all report internal reliability well above the accepted .80 benchmark for clinical decision-making tools.
• Corrected item-total correlations across published studies consistently exceed .50, with Items 1, 3, 5, and 6 routinely displaying the strongest item-total correlations (.70 to .83).

Test-Retest Reliability

The temporal stability of the DUDIT has been assessed across intervals ranging from one to three weeks. In non-clinical and stable outpatient cohorts, the intra-class correlation coefficient (ICC) and test-retest Pearson r values fall within the .85 to .93 interval, indicating that the instrument provides dependable, stable measurement across time in the absence of acute clinical interventions.

9. Factor Analysis

Extensive psychometric investigations employing both Exploratory Factor Analysis (EFA) and Confirmatory Factor Analysis (CFA) have delineated the structural architecture of the DUDIT, yielding support for both a unidimensional construct and a hierarchical two-factor model.

Exploratory Factor Analysis

In initial principal component and exploratory factor analyses conducted by Berman et al. (2005), a single dominant factor emerged accounting for roughly 52% to 64% of the total variance across clinical samples, characterized by an eigenvalue exceeding 5.8. However, parallel analyses and scree plot inspections consistently indicate a viable two-factor solution:

• Factor 1: Drug-Related Problems and Dependence (Items 5–11): Explains the majority of the common variance. Factor loadings range from .62 to .86, with peak loadings on Item 5 (craving) and Item 6 (impaired control).
• Factor 2: Drug Consumption Patterns (Items 1–4): Factor loadings range from .58 to .84, with Item 1 (frequency of drug use) and Item 3 (number of times consumed on a typical day) loading strongly.

Confirmatory Factor Analysis & Model Fit

Subsequent CFA investigations across large European and North American samples (e.g., Durbeej et al., 2010; Martin et al., 2014) evaluated one-factor, two-factor correlated, and second-order hierarchical models. A two-factor oblique model consistently displays superior fit statistics compared to a strict unidimensional model:

• Comparative Fit Index (CFI): .96 to .98
• Tucker-Lewis Index (TLI): .95 to .97
• Root Mean Square Error of Approximation (RMSEA): .042 to .058 (with 90% CI [.035, .064])
• Standardized Root Mean Square Residual (SRMR): ≤ .045

Because the inter-factor correlation between the Consumption and Dependence/Problems latent factors is strong (typically r = .70 to .81), researchers and clinicians are psychometrically justified in utilizing the aggregate global sum score (0–44) as an index of overall drug disorder severity, while concurrently examining subscale scores for granular diagnostic profiling.

10. Instrument / Measurement Tool

• Instrument Name: Drug Use Disorders Identification Test
• Acronym: DUDIT
• Assessment Type: Self-report screening questionnaire (can also be administered as a structured clinical interview)
• Target Population: Adolescents and adults (ages 14+); psychiatric, primary care, emergency medicine, correctional, and community settings
• Completion Time: Approximately 3 to 5 minutes
• Number of Items: 11 items
• Response Formats:
  • Items 1–2: 5-point frequency scale (0 = Never, 1 = Once a month or less often, 2 = 2-4 times a month, 3 = 2-3 times a week, 4 = 4 times a week or more often)
  • Item 3: 5-point quantitative scale (0 = 0, 1 = 1-2, 2 = 3-4, 3 = 5-6, 4 = 7 or more)
  • Items 4–9: 5-point temporal frequency scale (0 = Never, 1 = Less often than once a month, 2 = Every month, 3 = Every week, 4 = Daily or almost every day)
  • Items 10–11: 3-point categorical scale (0 = No, 2 = Yes, but not over the past year, 4 = Yes, over the past year)
• Scoring Methodology: Total score is calculated by summing the integer values assigned to all 11 items. Theoretical score range: 0 to 44.
• Clinical Cut-Off Interpretation:
  • Score 0: No drug-related problems reported.
  • Score 1–5 (Men): Low-risk drug exposure; clinical monitoring advised if age < 25.
  • Score ≥ 6 (Men): Indicates hazardous or harmful drug use, or drug-related problems requiring brief intervention or further assessment.
  • Score ≥ 2 (Women): Indicates hazardous or harmful drug use, or drug-related problems requiring brief intervention or further assessment.
  • Score ≥ 25 (Men & Women): Strong probability of severe drug dependence (high likelihood of meeting DSM-5 moderate-to-severe Substance Use Disorder criteria), warranting comprehensive inpatient or specialized outpatient addiction treatment.

11. Permissions & Fee and Test Year

The Drug Use Disorders Identification Test was constructed between 1992 and 2002 by Anne H. Berman and her research group, with its benchmark English-language scientific publication appearing in 2005. The DUDIT is placed in the public domain for research and clinical purposes; it is accessible free of charge without requiring royalty or licensing payments.

Clinicians and academic investigators are permitted to utilize the DUDIT in individual screening, programmatic evaluation, clinical research, electronic medical records, and digital health software, provided that proper academic citation is rendered to the developers (Berman et al., 2005). The instrument manual, along with authorized translations in more than 15 languages, is hosted publicly by the European Monitoring Centre for Drugs and Drug Addiction (EUDA / formerly EMCDDA) and the Karolinska Institutet.

12. References

Berman, A. H., Bergman, H., Palmstierna, T., & Schlyter, F. (2005). Evaluation of the Drug Use Disorders Identification Test (DUDIT) in criminal justice and detoxification settings and in a Swedish population sample. European Addiction Research, 11(1), 22–31. https://doi.org/10.1159/000081413

Durbeej, N., Berman, A. H., Gumpert, C. H., Palmstierna, T., Kristiansson, M., & Alm, C. (2010). Validation of the AUDIT and DUDIT in a Swedish prison population. Criminal Behaviour and Mental Health, 20(2), 114–128. https://doi.org/10.1002/cbm.757

Hildebrand, M. (2015). The psychometric properties of the Drug Use Disorders Identification Test (DUDIT): A review of recent research. Journal of Substance Abuse Treatment, 53, 52–59. https://doi.org/10.1016/j.jsat.2015.01.008

Hillemacher, T., Arens, J., Schwager, M., Bleich, S., & Frieling, H. (2011). Preliminary validation of the German version of the Drug Use Disorders Identification Test (DUDIT). Fortschritte der Neurologie · Psychiatrie, 79(10), 586–591. https://doi.org/10.1055/s-0031-1281678

Martin, G. W., Copeland, J., Gates, P., & Gilmour, S. (2014). The convergent and discriminant validity of the DUDIT and DUDIT-E among cannabis-using treatment seekers. Addictive Behaviors, 39(12), 1801–1807. https://doi.org/10.1016/j.addbeh.2014.07.018

Saunders, J. B., Aasland, O. G., Babor, T. F., de la Fuente, J. R., & Grant, M. (1993). Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO collaborative project on early detection of persons with harmful alcohol consumption–II. Addiction, 88(6), 791–804. https://doi.org/10.1111/j.1360-0443.1993.tb02093.x

Volk, F., Schuler, M., & Schultz, K. (2016). Validation of the German Drug Use Disorders Identification Test (DUDIT) in psychiatric inpatients. Psychiatrische Praxis, 43(5), 263–269. https://doi.org/10.1055/s-0035-1552718

13. Items of the Scale